First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK1) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
机构:[1]Medical Oncology, National Cancer Centre Singapore, Singapore,[2]Internal Medicine,Songklanagarind Hospital, Hat Yai, Songkhla, Thailand,[3]Internal Medicine, NationalTaiwan University Hospital, Taipei, Taiwan,[4]Department of Oncology, Taipei VeteransGeneral Hospital, Taipei, Taiwan,[5]Internal Medicine, China Medical University Hospital,Taichung, Taiwan,[6]Department of Respiratory Disease, Thoracic Disease Center, TheFirst Affiliated Hospital, Zhejiang University, Hangzhou, China,浙江大学医学院附属第一医院[7]Department of LungCancer Surgery, General Hospital of Tianjin Medical University, Tianjin, China,[8]Divisionof Pulmonary and Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital,Kaohsiung, Taiwan,中山大学附属第二医院[9]Internal Medicine Oncology, Sichuan Province Cancer Hospital,Chengdu, China,四川省肿瘤医院[10]Medical Oncology, The First Affiliated Hospital of GuangzhouMedical University, Guangdong Sheng, China,[11]Tumor Center, The First Hospital of JilinUniversity, Changchun, China,[12]Department of Thoracic Oncology, West ChinaHospital of Sichuan University, Chengdu, China,[13]Internal Medicine, ChulalongkornUniversity and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand,中山大学附属第二医院[14]Thoracic Medicine, Chang Gung Memorial Hospital (Linko), Taoyuan, Taiwan,[15]Clinical Development and Analytics, Novartis Pharmaceutical Corporation, EastHanover, NJ, USA,[16]Global Drug Development, Novartis Pharma AG, Basel, Switzerland,[17]Clinical Development, Novartis Pharmaceutical Corporation, East Hanover, NJ, USA,[18]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital,Guangzhou, China广东省人民医院
第一作者机构:[1]Medical Oncology, National Cancer Centre Singapore, Singapore,
推荐引用方式(GB/T 7714):
D.S. Tan,S. Geater,C.J. Yu,et al.First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK1) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis[J].ANNALS OF ONCOLOGY.2019,30:599-600.
APA:
D.S. Tan,S. Geater,C.J. Yu,C.M. Tsai,T.C. Hsia...&Y.L. Wu.(2019).First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK1) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis.ANNALS OF ONCOLOGY,30,
MLA:
D.S. Tan,et al."First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK1) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis".ANNALS OF ONCOLOGY 30.(2019):599-600